Rezolute's Drug Lets Tumor Patients Ditch IV Glucose — But Can a 16-Person Trial Justify a $430 Million Bet?

Shares of Rezolute surged as much as 12.3% to $4.49 in pre-market trading, capping a week-long rally of roughly 37% from $3.27, after the company posted interim results showing its experimental drug can free rare-cancer patients from round-the-clock IV glucose drips. For a company still reeling from a failed trial in a separate condition last December, the data offer a lifeline — but the path from here is narrow.

Six of Eight Patients Hit the Mark, and That's the Entire Bull Case Right Now. Of the 8 patients enrolled so far, 6 met the trial's primary goal: at least a 50% reduction in IV glucose needs within eight weeks of treatment. More strikingly, each of those 6 patients also completely stopped needing IV glucose altogether.

All patients who completed the pivotal phase chose to continue into a long-term extension, with treatment durations up to six months and no drug-related adverse events reported. For investors, clean safety data at this stage reduces the risk of a regulatory rejection on toxicity grounds.

A Tiny Trial in an Ultra-Rare Disease Means Big Uncertainty. The study targets just 16 total patients and is only 50% enrolled.

One patient withdrew due to advanced cancer progression and was counted as a non-responder.

Topline results from the fully enrolled study are expected in the second half of 2026. With such small numbers, even one or two non-responders among the remaining eight could meaningfully shift the overall response rate and complicate the FDA submission.

Last Year's Failure in a Bigger Market Still Looms Large. In December 2025, Rezolute's Phase 3 trial in congenital hyperinsulinism — a potentially larger market — failed to meet its primary endpoint.

Cantor Fitzgerald holds a Neutral rating following FDA discussions about that setback. The tumor indication now carries the company's near-term hopes, but tumor hyperinsulinism is exceedingly rare, with limited treatment options — meaning even a successful approval may yield modest revenue.

Cash Buys Time, but the Burn Rate Is Steep. Rezolute reported $132.9 million in cash as of December 2025 and a quarterly net loss of $22.8 million — roughly six quarters of runway without further fundraising. The most recent analyst price target sits at $10.00 with a Buy rating , more than double today's price, but that assumes the trial succeeds and the FDA cooperates. At roughly $430 million in market value at today's price across ~96 million shares, Rezolute is a classic binary biotech wager: rewarding if the remaining data hold, painful if they don't.